Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) (ERMES study)

被引：0
|
作者：
Normanno, Nicola
Orlandi, Armando
Maiello, Evaristo
Rachiglio, Anna Maria
Maglietta, Giuseppe
Damato, Angela
Calegari, Maria Alessandra
Antonuzzo, Lorenzo
Bordonaro, Roberto
Zampino, Maria Giulia
Tamberi, Stefano
Lonardi, Sara
Tonini, Giuseppe
Rosati, Gerardo
Latiano, Tiziana Pia
Tamburini, Emiliano
Maiello, Monica Rosaria
Carotenuto, Marianeve
Barone, Carlo
Pinto, Carmine
机构：
[1] Ist Nazl Tumori IRCCS Fdn Pascale, Cell Biol & Biotherapy Unit, Naples, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, UOC Oncol Med, Rome, Italy
[3] Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy
[4] Ist Nazl Tumori IRCCS Fdn G Pascale, Cell Biol & Biotherapy Unit, Naples, Italy
[5] Univ Hosp Parma, Clin & Epidemiol Res Unit, Parma, Italy
[6] AUSL IRCCS Reggio Emilia, Comprehens Canc Center, Med Oncol Unit, Reggio Emilia, Italy
[7] Fdn Policlin Univ Agostino Gemelli IRCCS, Ctr Comprehens Canc, Oncol Med, Rome, Italy
[8] Careggi Univ Hosp, Dept Expt & Clin Med, Clin Oncol Unit, Florence, Italy
[9] Azienda Osped ARNAS Garibaldi, Med Oncol, Catania, CT, Italy
[10] Ist Europeo Oncol IRCCS, Med Oncol Deparment, Milan, Italy
[11] Santa Maria Croci Hosp, Oncol Unit, Ravenna, Italy
[12] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Padua, Italy
[13] Univ Campus Biomed, Dept Med Oncol, Rome, Italy
[14] Azienda Osped S Carlo, Potenza, Italy
[15] Fdn IRCCS Casa Sollievo Sofferenza, Oncol Unit, San Giovanni Rotondo, Italy
[16] Tricase City Hosp, Dept Oncol, Tricase, Italy
[17] Policlin Univ Agostino Gemelli, UOC Oncol Med, Rome, Italy
[18] AUSL IRCCS, Med Oncol Unit, Ctr Comprehens Canc, Reggio Emilia, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3544
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
    Pinto, C.
    Orlandi, A.
    Normanno, N.
    Maiello, E.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Pini, S.
    Bergamo, F.
    Tonini, G.
    Avallone, A.
    Latiano, T. P.
    Rosati, G.
    Pazzola, A.
    Ballestrero, A.
    Zaniboni, A.
    Roselli, M.
    Tamberi, S.
    Barone, C. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1390
  • [2] Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study).
    Normanno, Nicola
    Rachiglio, Anna Maria
    Abate, Riziero Esposito
    Orlandi, Armando
    Maiello, Evaristo
    Maglietta, Giuseppe
    Damato, Angela
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Avallone, Antonio
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Barone, Carlo Antonio
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES)
    Normanno, N.
    Rachiglio, A. M.
    Abate, R. Esposito
    Orlandi, A.
    Maiello, E.
    Maglietta, G.
    Damato, A.
    Maiello, M. R.
    Carotenuto, M.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Tamberi, S.
    Lonardi, S.
    Avallone, A.
    Latiano, T. P.
    Tamburini, E.
    Barone, C. A.
    Pinto, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S52 - S52
  • [4] Phase III study with FOLFIRI plus cetuximab versus FOLFIRI plus cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC
    Pinto, Carmine
    Normanno, Nicola
    Orlandi, Armando
    Fenizia, Francesca
    Damato, Angela
    Maiello, Evaristo
    Tamburini, Emiliano
    Di Costanzo, Francesco
    Tonini, Giuseppe
    Bilancia, Domenico
    Corsi, Domenico
    Pisconti, Salvatore
    Ferrau, Francesco
    Gori, Stefania
    Daniele, Bruno
    Zaniboni, Alberto
    Parra, Hector Soto
    Frassinetti, Giovanni Luca
    Iaffaioli, Rosario Vincenzo
    Cassata, Antonio
    Zampino, Maria Giulia
    Repetto, Lazzaro
    Calegari, Maria Alessandra
    Barone, Carlo
    FUTURE ONCOLOGY, 2018, 14 (14) : 1339 - 1346
  • [5] Cetuximab metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI plus cetuximab until disease progression compared to FOLFIRI plus cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer.
    Pinto, Carmine
    Normanno, Nicola
    Orlandi, Armando
    Maiello, Evaristo
    Bilancia, Domenico
    Corsi, Domenico C.
    Tamburini, Emiliano
    Pisconti, Salvatore
    Ferrau, Francesco
    Di Costanzo, Francesco
    Gori, Stefania
    Daniele, Bruno
    Tonini, Giuseppe
    Zaniboni, Alberto
    Soto-Parra, Hector
    Frassinetti, Giovanni Luca
    Iaffaioli, Rosario Vincenz
    Zampino, M. Giulia
    Repetto, Lazzaro
    Barone, Carlo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [6] Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study
    Pinto, Carmine
    Orlandi, Armando
    Normanno, Nicola
    Maiello, Evaristo
    Calegari, Maria A.
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria G.
    Pini, Sara
    Bergamo, Francesca
    Tonini, Giuseppe
    Avallone, Antonio
    Latiano, Tiziana P.
    Rosati, Gerardo
    Cogoni, Alessio Aligi
    Ballestrero, Alberto
    Zaniboni, Alberto
    Roselli, Mario
    Tamberi, Stefano
    Barone, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1278 - 1287
  • [7] Efficacy and safety of first-line cetuximab plus FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.
    Van Cutsem, Eric
    Kohne, Claus-Henning
    Folprecht, Gunnar
    Guenther, Silke
    Beier, Frank
    Papamichael, Demetris
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [8] Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)
    Cervantes, A.
    Macarulla, T.
    Martinelli, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Stroh, C.
    Nippgen, J.
    Baselga, J.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Randomized phase II study of duligotuzumab plus FOLFIRI versus cetuximab plus FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Hill, Andrew G.
    Findlay, Michael
    Burge, Matthew
    Jackson, Christopher
    Garcia Alfonso, Pilar
    Samuel, Leslie
    Ganju, Vinod
    Karthaus, Meinolf
    Amatu, Alessio
    Jeffery, Mark
    DiBartolomeo, Maria
    Bridgewater, John
    Coveler, Andrew
    Hidalgo, Manuel
    Kapp, Amy V.
    Sufan, Roxana
    McCall, Bruce
    Penuel, Elicia
    Pirzkall, Andrea
    Tabernero, Josep
    CANCER RESEARCH, 2015, 75
  • [10] Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI plus cetuximab in the CRYSTAL study
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Guenther, S.
    Von Hohnhorst, P.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S371
12345